Last week’s top gainer was Tobira Therapeutics, followed by Northwest Biotherapeutics, Sarepta Therapeutics, Novavax and Galectin Therapeutics.
The NASDAQ Biotechnology index (INDEXNASDAQ:NBI) slowly inched upwards to a high of 3,148.862 on Friday, but ended the five day trading week with 3,118.59 points, down by 0.60 percent.
Last week’s top companies recorded over 60 percent gains for the week. Here is a look at how the companies performed last week.
- Tobira Therapeutics (NASDAQ:TBRA)
- Northwest Biotherapeutics (NASDAQ:NWBO)
- Sarepta Therapeutics (NASDAQ:SRPT)
- Novavax (NASDAQ:NVAX)
- Galectin Therapeutics (NASDAQ:GALT)
Tobira Therapeutics gained 752.07 percent over the five day trading period and 289.15 percent year to date. Tobira ended the week at $39.11 per share.
Tobira is focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. Last week, Tobira announced that it had entered into a definitive agreement with Allergan (NYSE:AGN)) whereby Allergan will acquire Tobira for a total potential consideration of up to $1.695 billion. The transaction is anticipated to close by the end of 2016.
Northwest Biotherapeutics is no stranger to our weekly lists of top gainers. This week, the stock gained 108.33 percent over the five day trading period, and ended the week at $0.53 cents per share.
Northwest Biotherapeutics is developing personalized vaccines for solid tumor cancers. Last week, the company announced that Chief Technical Officer, Dr. Marnix Bosch, presented an updated and more detailed analysis of the Phase I DCVax®-Direct Trial data at the 5th Annual SMi Cancer Vaccines Conference in London, England. Dr. Bosch reported that the top 20 percent of the clinical trial patients have so far exceeded 2 years of survival and are still alive, as well as other positive results.
Sarepta Therapeutics gained 105.44 percent over the five day trading period, and ended the week at $57.83 per share .
Sarepta is developing RNA-based technologies for the treatment of and infectious diseases. Last week, the company announced that it has priced an underwritten public offering of an aggregate of 5.02 million shares of its common stock at a price to the public of $59.75 per share.
Novavax gained 75.19 percent over the five day trading period, and ended the week at $2.26 per share.
Novavax is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. On September 15, Novavax reported topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate in older adults. There has been no further recent news from the company to explain last week’s rise in share price.
Galectin gained 60.59 percent over the five day trading period, and ended the week at $2.73 per share.
Galectin is a clinical-stage biopharmaceutical company focused on drug research and development to create therapies for fibrotic disease and cancer. On August 25, the company announced results from its exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. There has been no further recent news from the company to explain last week’s rise in share price.
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Pia Rivera, hold no direct investment interest in any company mentioned in this article.